RxDoctor Payments Data

Jeff Segrest, MD

Cardiovascular Disease · Clanton, ALNPI 1841384724

Payments from drug & device makers

$3,112in general payments, 2019–2025

Across 43 payments — averaging $72.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$2K
  • Abbott$270
  • Novartis$231
  • Bard Peripheral Vascular, Inc.$85
  • Pfizer$68
  • E.r. Squibb & Sons, L.L.C.$57
  • plus $136 from 6 others

What the payments were for

  • Food & beverage$86228%
  • Other$2,25072%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,112 in reported general payments places this provider in the 45th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$346,184
Medicare patients
734
Services billed
3,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban523$452,512
XareltoRivaroxaban69$72,533
Repatha SureclickEvolocumab60$46,646
BrilintaTicagrelor75$43,434
EntrestoSacubitril/Valsartan43$34,560
FarxigaDapagliflozin Propanediol23$18,732
Ranolazine ErRanolazine41$7,134
Metoprolol Succinate437$5,665
Atorvastatin Calcium314$4,667
ClopidogrelClopidogrel Bisulfate210$2,259
Rosuvastatin Calcium110$2,132
Amlodipine Besylate216$1,478
Lisinopril142$1,438
Metoprolol Tartrate173$1,410
Isosorbide Dinitrate22$1,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$452,512523 claims
AstraZenecaBrilinta, Farxiga$14$62,16698 claims
NovartisEntresto$231$34,56043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Clanton

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →